{
    "Trade/Device Name(s)": [
        "PF4 Enhanced assay",
        "PF4/PVS Anti-IgG/A/M Antibody Detection Assay",
        "Platelet Factor 4 Assay"
    ],
    "Submitter Information": "Immucor GTI Diagnostics, Inc.",
    "510(k) Number": "K201570",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053559"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCO"
    ],
    "Summary Letter Date": "September 11, 2020",
    "Summary Letter Received Date": "June 11, 2020",
    "Submission Date": "June 11, 2020",
    "Regulation Number(s)": [
        "21CFR864.7695"
    ],
    "Regulation Name(s)": [
        "Platelet Factor 4 Radioimmunoassay"
    ],
    "Analyte Class(es)": [
        "immunology",
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Antibodies to Platelet Factor 4 (PF4) complexed to polyanionic compounds"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium Citrate Plasma"
    ],
    "Specimen Container(s)": [
        "Without anticoagulant tube (Serum)",
        "3.2% sodium citrate tube (Plasma)"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme Linked Immunosorbent Assay (ELISA)",
        "Colorimetric measurement"
    ],
    "Methodologies": [
        "Qualitative ELISA antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Immucor GTI PF4 Enhanced assay, a qualitative ELISA for detection of antibodies against PF4 complexes in serum or plasma, with positive control and stopping solution modifications",
    "Indications for Use Summary": "Intended as a qualitative ELISA to assist laboratories in screening for antibodies associated with heparin induced thrombocytopenia (HIT) or thrombosis in patients undergoing heparin therapy",
    "fda_folder": "Hematology"
}